Medicus Pharma To To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026 - Medicu

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic

Raccontata dabenzinga.com